Windlas Biotech (NSE:WINDLAS) Tax Provision: ₹-205 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
87 GF Score
Price ₹844.25
GF Value ₹941.82
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Tax Provision?

Windlas Biotech NSE:WINDLAS -0.71% 87 Tax Provision is ₹-205 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 87/100 and a GF Value™ of ₹941.82 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Windlas Biotech's tax provision for the three months ended in Mar. 2026 was ₹-42 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-205 Mil.

Windlas Biotech Tax Provision Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Tax Provision Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Provision
Get a 7-Day Free Trial -74.76 -144.13 -189.04 -187.64 -205.21

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.42 -55.93 -57.88 -49.69 -41.71
NSE:WINDLAS
87GF Score
Windlas Biotech Ltd NSE:WINDLAS
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-205 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ₹-205 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Tax Provision of ₹-205 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Tax Provision too high?
Windlas Biotech's current Tax Provision is ₹-205 Mil. Overall, Windlas Biotech has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Tax Provision compare to ZTS and UTHR?
Windlas Biotech's Tax Provision of ₹-205 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Tax Provision is ₹-205 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹941.82, compared to a current price of ₹844.25 — trading 10.4% below its estimated fair value. The current Tax Provision is ₹-205 Mil. Windlas Biotech's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Tax Provision is ₹-205 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹844.25 is trading 10.4% below its estimated GF Value™ of ₹941.82. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Tax Provision: ₹-205 Mil
  • GF Value™: ₹941.82 vs. price of ₹844.25 (10.4% below fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score

Get the complete analysis for NSE:WINDLAS

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹844.25
Price
₹941.82
GF Value